About roche holding ag - RHHBY
Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
RHHBY At a Glance
Roche Holding AG
Grenzacherstrasse 124
Basel, Basel-Stadt (Basle Town) 4058
| Phone | 41-61-688-11-11 | Revenue | 68.69B | |
| Industry | Pharmaceuticals: Major | Net Income | 9.40B | |
| Sector | Health Technology | 2024 Sales Growth | 5.134% | |
| Fiscal Year-end | 12 / 2025 | Employees | 103,249 | |
| View SEC Filings |
RHHBY Valuation
| P/E Current | 28.438 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.662 |
| Price to Sales Ratio | 3.258 |
| Price to Book Ratio | 6.332 |
| Price to Cash Flow Ratio | 10.275 |
| Enterprise Value to EBITDA | 10.149 |
| Enterprise Value to Sales | 3.634 |
| Total Debt to Enterprise Value | 0.161 |
RHHBY Efficiency
| Revenue/Employee | 665,306.282 |
| Income Per Employee | 91,028.02 |
| Receivables Turnover | 4.616 |
| Total Asset Turnover | 0.625 |
RHHBY Liquidity
| Current Ratio | 1.482 |
| Quick Ratio | 1.20 |
| Cash Ratio | 0.641 |
RHHBY Profitability
| Gross Margin | 73.509 |
| Operating Margin | 30.14 |
| Pretax Margin | 19.569 |
| Net Margin | 13.682 |
| Return on Assets | 8.551 |
| Return on Equity | 26.898 |
| Return on Total Capital | 12.503 |
| Return on Invested Capital | 13.791 |
RHHBY Capital Structure
| Total Debt to Total Equity | 114.44 |
| Total Debt to Total Capital | 53.367 |
| Total Debt to Total Assets | 35.711 |
| Long-Term Debt to Equity | 101.039 |
| Long-Term Debt to Total Capital | 47.118 |